

## PRODUCT MONOGRAPH

### **PrRIVA-PANTOPRAZOLE**

Pantoprazole Delayed-Release tablets

40 mg Pantoprazole (as pantoprazole sodium sesquihydrate)

H<sup>+</sup>, K<sup>+</sup>-ATPase Inhibitor

**Laboratoire Riva Inc.**  
660 Boul. Industriel  
Blainville, QC  
J7C 3V4  
[www.labriva.com](http://www.labriva.com)

Date of Revision: July 03, 2018

Submission Control No: 216832

## **Table of Contents**

<b>PART I: HEALTH PROFESSIONAL INFORMATION .....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS .....	4
WARNINGS AND PRECAUTIONS .....	4
ADVERSE REACTIONS .....	7
DRUG INTERACTIONS .....	10
DOSAGE AND ADMINISTRATION.....	12
OVERDOSAGE .....	13
ACTION AND CLINICAL PHARMACOLOGY .....	13
STORAGE AND STABILITY .....	15
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	15
<b>PART II: SCIENTIFIC INFORMATION .....</b>	<b>17</b>
PHARMACEUTICAL INFORMATION .....	17
CLINICAL TRIALS .....	18
DETAILED PHARMACOLOGY .....	23
TOXICOLOGY .....	26
REFERENCES .....	32
<b>PART III: PATIENT MEDICATION INFORMATION .....</b>	<b>34</b>

**Pr RIVA-PANTOPRAZOLE**

Pantoprazole Delayed-Release Tablet  
Pantoprazole sodium sesquihydrate

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form/ Strength</b>	<b>All Non-medicinal Ingredients</b>
oral	Delayed-Release Tablet 40 mg pantoprazole (as pantoprazole sodium sesquihydrate)	Calcium stearate, cellulose microcrystalline, crospovidone, ferric oxide yellow, hydroxypropylcellulose, hypromellose, macrogol, methacrylic acid – ethyl acrylate copolymer, polysorbate 80, ponceau 4R aluminium lake, povidone, quinoline yellow aluminium lake, silica-colloidal anhydrous, sodium carbonate anhydrous, sodium laurilsulfate, titanium dioxide, triethyl citrate.

**INDICATIONS AND CLINICAL USE**

RIVA-PANTOPRAZOLE (pantoprazole sodium sesquihydrate) is indicated for the treatment of conditions where a reduction of gastric acid secretion is required, such as the following:

- Duodenal ulcer
- Gastric ulcer
- Reflux esophagitis
- Symptomatic gastro-esophageal reflux disease (such as, acid regurgitation and heartburn).
- Prevention of gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs (NSAIDs) in patients with a need for continuous NSAID treatment, who have increased risk to develop NSAID-associated upper gastrointestinal lesions.

For the maintenance treatment of patients with reflux esophagitis and the resolution of symptoms associated with reflux esophagitis, such as heartburn with or without regurgitation, 20 or 40 mg pantoprazole once daily have been used for 3 years in controlled clinical trials. In continuous maintenance treatment 20 mg pantoprazole has been used in a limited number of patients for up to eight years.

**Geriatrics (>65 years of age):**

No dose adjustment is recommended based on age. The daily dose used in elderly patients, as a rule, should not exceed the recommended dosage regimens. See PHARMACOLOGY.

**Pediatrics:**

The safety and effectiveness of pantoprazole in children have not yet been established.

**CONTRAINDICATIONS**

Patients who are hypersensitive to pantoprazole, substituted benzimidazoles, or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.

Co-administration with rilpivirine is contraindicated.

**WARNINGS AND PRECAUTIONS****General**

In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, hematemesis, anemia, or melena) and when gastric ulcer is suspected, the possibility of malignancy should be excluded before therapy with RIVA-PANTOPRAZOLE (pantoprazole sodium sesquihydrate) is instituted since treatment with pantoprazole sodium may alleviate symptoms and delay diagnosis. Further investigation should be considered if symptoms persist despite adequate treatment. In long-term treatment, patients should be kept under regular surveillance.

***Clostridium difficile*-Associated Diarrhea**

Decreased gastric acidity due to any means, including proton pump inhibitors (PPIs), increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with PPIs can lead to an increased risk of gastrointestinal infections such as *Salmonella*, *Campylobacter* and *Clostridium difficile*.

An increased risk for *Clostridium difficile* infection (CDI) and *Clostridium difficile*-associated diarrhea (CDAD) has been observed in association with PPI use in several observational studies. CDI/CDAD should be considered in the differential diagnosis for diarrhea that does not improve. Additional risk factors for CDI and CDAD include recent hospitalization, the use of antibiotics, old age and the presence of co-morbidities.

Patients should be prescribed PPIs at the lowest dose and for the shortest duration required for the condition being treated and be reassessed to ascertain whether continued PPI therapy remains beneficial.

**Concomitant Use with Methotrexate**

Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. A temporary withdrawal of the PPI may be considered in some patients receiving treatments with high dose methotrexate.

## **Bone Fracture**

Several published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines (see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS).

## **Carcinogenesis and Mutagenesis**

Effects of long-term treatment include hypergastrinemia, possible enterochromaffin-like (ECL) cell hyperplasia and carcinoid formation in the stomach, adenomas and carcinomas in the liver and neoplastic changes in the thyroid.

In the rat, the mechanism leading to the formation of gastric carcinoids is considered to be due to the elevated gastrin level occurring during chronic treatment. Similar observations have also been made after administration of other acid secretion inhibitors. (For further details, see TOXICOLOGY).

Short-term and long-term treatment with pantoprazole sodium in a limited number of patients up to 6 years have not resulted in any significant pathological changes in gastric oxytic exocrine cells.

## **Drug Interactions with Antiretroviral Drugs**

PPIs have been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. A change in gastric pH may change the absorption of the antiretroviral drug. Other possible mechanisms are via CYP 2C19.

### **Rilpivirine**

Co-administration is contraindicated due to significant decrease in rilpivirine exposure and loss of therapeutic effect (see CONTRAINDICATIONS).

### **Atazanavir and Nelfinavir**

Co-administration with atazanavir or nelfinavir is not recommended due to decreased atazanavir and nelfinavir exposure (see the REYATAZ® and VIRACEPT® Product Monographs). If the combination of pantoprazole with atazanavir is judged unavoidable, close clinical monitoring is recommended in combination with the use of 400 mg atazanavir/100 mg ritonavir dose; the dose of pantoprazole should not exceed an equivalent dose of omeprazole of 20 mg daily (see REYATAZ® Product Monograph).

### **Saquinavir**

If pantoprazole is co-administered with saquinavir/ritonavir, caution and monitoring for potential saquinavir toxicities, including gastrointestinal symptoms, increased triglycerides, deep vein thrombosis and QT prolongation, are recommended. Dose reduction of saquinavir should be considered from the safety perspective for individual patients (see INVIRASE® Product Monograph).

### **Hepatic/Biliary/Pancreatic & Renal**

The daily dose in patients with severe liver disease should, as a rule, not exceed 20 mg pantoprazole. See ACTION & CLINICAL PHARMACOLOGY, Special Populations & Conditions.

The daily dose used in renal insufficient patients, as a rule, should not exceed the recommended dosage regimens. See ACTION & CLINICAL PHARMACOLOGY, Special Populations & Conditions.

### **Endocrine and Metabolism**

#### **Hypomagnesemia**

Hypomagnesemia, symptomatic and asymptomatic, has been reported in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), healthcare professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically.

The chronic use of PPIs may lead to hypomagnesemia. Moreover, hypokalemia and hypocalcemia have been reported in the literature as accompanying electrolyte disorders.

#### **Cyanocobalamin (Vitamin B<sub>12</sub>) Deficiency**

The prolonged use of proton pump inhibitors may impair the absorption of protein-bound Vitamin B<sub>12</sub> and may contribute to the development of cyanocobalamin (Vitamin B<sub>12</sub>) deficiency.

#### **Interference with Laboratory Tests**

During treatment with antisecretory drugs, chromogranin A (CgA) increases due to decreased gastric acidity. Increased CgA levels may interfere with investigations for neuroendocrine tumours. To avoid this interference, RIVA-PANTOPRAZOLE treatment should be stopped 14 days before CgA measurements (see DRUG INTERACTIONS).

#### **Special Populations**

**Pregnant Women:** There are no adequate or well-controlled studies in pregnant women. Studies in animals have shown reproductive toxicity, the potential risk for humans is unknown.

Pantoprazole sodium should not be administered to pregnant women unless the expected benefits outweigh the potential risks to the fetus. See REPRODUCTION and TERATOLOGY.

**Nursing Women:** Animal studies have shown excretion of pantoprazole in breast milk. Excretion into human milk has been reported. Pantoprazole sodium should not be given to nursing mothers unless its use is believed to outweigh the potential risks to the infant.

**Pediatrics:** The safety and effectiveness of pantoprazole in children have not yet been established.

**Geriatrics (> 65 years of age):** No dose adjustment is recommended based on age. The daily dose used in elderly patients, as a rule, should not exceed the recommended dosage regimens. See PHARMACOLOGY. Benefits of use of PPIs should be weighed against the increased risk of fractures as patients in this category (> 71 years of age) may already be at high risk for osteoporosis-related fractures. If the use of PPIs is required, they should be managed carefully according to established treatment guidelines (see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS).

## ADVERSE REACTIONS

### Adverse Drug Reaction Overview

Pantoprazole sodium is well tolerated. Most adverse events have been mild and transient showing no consistent relationship with treatment.

The following adverse events (the most frequently reported) have been reported in individuals receiving pantoprazole therapy (40 mg once daily) in controlled clinical trials of at least 6 months duration: headache (2.1%), diarrhea (1.6%), nausea (1.2%).

### Clinical Trial Adverse Drug Reactions

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

Adverse events have been recorded during controlled clinical investigations in over 13,000 patients exposed to pantoprazole sodium as the single therapeutic agent for treatment of conditions requiring acid suppression. The following adverse reactions considered possibly, probably, or definitely related by the investigator have been reported in individuals receiving pantoprazole therapy (20 mg or 40 mg once daily) in long-term clinical trials (duration of at least 6 months).

**Adverse drug reactions with a frequency of ≥1%, related to 40 mg pantoprazole, assessed as possibly, probably or definitely related by the investigator**

Preferred term	Number of patients	Percentage of patients
Headache	24	2.137
Diarrhea	18	1.603
Nausea	13	1.158

For long-term treatment with 20 mg, no such events were reported with a frequency of more than 1%.

### Adverse drug reactions with a frequency of 0.1 to 1% related to 20 mg pantoprazole

Gastrointestinal Disorders: Diarrhea, Flatulence, Abdominal pain, Abdominal pain upper, Abdominal distension, Gastric polyps, Loose stools, Frequent bowel movements, Eruption, Dyspepsia, Nausea, Vomiting, Constipation.

General Disorders: Fatigue.

Hepatobiliary Disorders: Alanine aminotransferase increased, Aspartate aminotransferase increased, Liver function tests abnormal, Transaminases increased.

Laboratory Parameters: Hyperglycemia.

Nervous System Disorders: Headache, Dizziness, Vertigo.

Skin and Subcutaneous Tissue Disorders: Pruritus, Rash.

Special Senses: Visual disturbance.

Other: Libido decreased.

#### **Adverse drug reactions with a frequency of 0.1 to 1% related to 40 mg pantoprazole**

Cardiovascular System: Blood pressure increased, Hypertension, ECG abnormal.

Gastrointestinal Disorders: Flatulence, Abdominal distension, Abdominal pain, Abdominal pain upper, Loose stools, Esophageal reflux aggravated, Gastric polyps, Abdominal discomfort, Abdominal tenderness, Constipation, Eructation, Vomiting, Dyspepsia, Gastroesophageal Reflux, Esophagitis.

General Disorders: Fatigue, Peripheral edema, Pyrexia.

Hepatobiliary Disorders: Alanine aminotransferase increased, Aspartate aminotransferase increased, Liver function tests abnormal, Transaminases increased.

Laboratory Parameters: Hypertriglyceridemia.

Metabolic and Nutritional: Appetite decreased, Weight increase.

Nervous System Disorders: Dysgeusia, Dizziness, Migraine, Vertigo.

Respiratory System: Cough.

Skin and Subcutaneous Tissue Disorders: Pruritus, Rash.

Special Senses: Mouth dry, Vision blurred.

Other: Neoplasm.

**The following adverse reactions considered possibly, probably, or definitely related by the investigator, have been reported in individuals receiving pantoprazole therapy (20 mg or 40 mg once daily) in short-term clinical trials (duration of up to 3 months).**

**Adverse drug reactions with a frequency of 0.1 to 1% related to pantoprazole, 20 or 40 mg**

Gastrointestinal Disorders: Diarrhea, Flatulence, Nausea, Constipation, Abdominal pain.

Nervous System Disorders: Headache, Dizziness.

Skin and Subcutaneous Tissue Disorders: Pruritus.

**In addition, the following adverse events considered unrelated, or unlikely related by the investigator have been reported in individuals receiving pantoprazole therapy (20 mg or 40 mg once daily) in short-term and long-term clinical trials.**

**Adverse events with a frequency of ≥1 %, 20 or 40 mg**

Influenza like illness, headache, diarrhea.

**Adverse events with a frequency of 0.1 to 1%, 20 or 40 mg**

Bronchitis, Nausea, Back pain, Abdominal pain upper, Upper respiratory tract infection, Non-accidental injury, Sinusitis, Abdominal pain, Dizziness, Arthralgia, Vomiting, Pharyngitis, Chest pain, Gastroenteritis, Dyspepsia, Urinary tract infection, Eruption, Pyrexia, Cough, Depression, Hypertension, Pain in limb, Constipation, Fatigue, Operation, Neck pain, Nasopharyngitis, Alanine aminotransferase increased, Hemorrhoids, Pain, Flatulence, Viral infection, Hypertriglyceridemia, Toothache, Hypersensitivity, Rash, Abdominal pain lower, Pneumonia, Abdominal distension, Dyspnoea, Muscle cramp, Rhinitis, Peripheral edema, Tonsillitis, Angina pectoris, Cholelithiasis, Sinus congestion, Influenza, Vertigo, Insomnia, Infection, Osteoarthritis, Hypercholesterolemia, Pruritus, Eczema, Sleep disorder, Migraine, Aspartate aminotransferase increased, Hyperglycemia, Musculoskeletal discomfort, Blood triglycerides increased, Myocardial infarction, Tendonitis, Weight increased, Rectal hemorrhage, Cystitis, Nasal Congestion, Arthritis, Contusion, Abdominal discomfort, Enteritis.

**The following Serious Adverse Events regardless of causality were reported with a frequency of <0.1% in either 20 mg or 40 mg**

Sepsis.

**Abnormal Hematological & Clinical Chemistry Findings**

Please refer to the Hepatobiliary Disorders and the Laboratory Parameters portions of the ADVERSE REACTION section, the ACTION & CLINICAL PHARMACOLOGY Special Populations & Conditions section, and the WARNINGS & PRECAUTIONS Hepatic/Biliary/Pancreatic section.

**Post-Market Adverse Drug Reactions**

The following adverse events were reported in post-marketing use and causal relation to pantoprazole sodium treatment could not be ruled out. As the events were reported spontaneously, no exact incidences can be provided:

Interstitial nephritis; Stevens-Johnson Syndrome; Erythema multiforme; Toxic epidermal necrolysis (Lyell syndrome); Photosensitivity; Hyponatremia; Hypomagnesemia; Hepatocellular injury; Jaundice; Hepatocellular failure; Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in the case of pre-existence). Hypokinesia, Anterior ischemic optic neuropathy; Pancreatitis; Increased salivation; Speech disorder; Elevated creatine phosphokinase; Rhabdomyolysis; Alopecia; Acne; Exfoliative dermatitis; Nervousness; Tremor; Tinnitus; Paresthesia; Photophobia; Vertigo; Increased appetite; Hematuria; Impotence; Eosinophilia, Osteoporosis and osteoporosis-related fractures.

In addition the following identified adverse drug reactions have been reported in oral pantoprazole sodium clinical trials in any indication and in any dosage:

Uncommon: Headache; Dizziness; Nausea/vomiting; Abdominal distension and bloating; constipation; dry mouth; Abdominal pain and discomfort; Rash/exanthema/eruption; Pruritus; Asthenia, fatigue and malaise; Liver enzymes increased (transaminases,  $\gamma$ -GT); Sleep disorders.

Rare: Agranulocytosis; Disturbances in vision/blurred vision; Urticaria; Angioedema; Myalgia; Arthralgia; Hyperlipidemias and lipid increases (triglycerides, cholesterol); Weight changes; Body temperature increased; Edema peripheral; Gynecomastia; Hypersensitivity (including anaphylactic reactions and anaphylactic shock); Bilirubin increased; Depression (and all aggravations); Taste Disorder.

Very rare: Thrombocytopenia; Leukopenia; Pancytopenia; Disorientation (and all aggravations).

Withdrawal of long-term PPI therapy can lead to aggravation of acid related symptoms and may result in rebound acid hypersecretion.

## **DRUG INTERACTIONS**

### **Overview**

Pantoprazole undergoes extensive hepatic metabolism via cytochrome P450-mediated oxidation. The main metabolic pathway is demethylation by CYP 2C19 and other metabolic pathways which include oxidation by CYP 3A4. This is followed by sulphate conjugation via a Phase II reaction (non-saturable, non-cytochrome P450 dependent). Pharmacokinetic drug interaction studies in man did not demonstrate the inhibition of the oxidative metabolism of the drug. No induction of the CYP 450 system by pantoprazole was observed during chronic administration of pantoprazole sodium with antipyrine as a marker. Pantoprazole causes long lasting inhibition of gastric acid secretion. Therefore, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of the bioavailability (e.g. ketoconazole, itraconazole, posaconazole, erlotinib).

### **Drug-Drug Interactions**

Pantoprazole sodium does not interact with carbamazepine, caffeine, diclofenac, naproxen, piroxicam, ethanol, glibenclamide, metoprolol, antipyrine, diazepam, phenytoin, nifedipine, theophylline, digoxin, oral contraceptives containing (levonorgestrel and ethinyl oestradiol), or

cyclosporine. Concomitant use of antacids does not affect the pharmacokinetics of pantoprazole sodium.

Although no interaction during concomitant administration of warfarin has been observed in clinical pharmacokinetic studies, a few isolated cases of changes in INR have been reported during concomitant treatment in the post-marketing period. Therefore, in patients being treated with coumarin anticoagulants, monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular use of pantoprazole.

Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted.

#### Rilpivirine

Co-administration is contraindicated due to significant decreases in rilpivirine exposure and loss of therapeutic effect (see CONTRAINDICATIONS).

#### Atazanavir

Co-administration of pantoprazole with atazanavir is not recommended. Concomitant administration of omeprazole (20 or 40 mg once daily) substantially reduced plasma C<sub>max</sub> and AUC of atazanavir in healthy volunteers administered atazanavir or atazanavir/ritonavir. (see REYATAZ® Product Monograph).

#### Nelfinavir

Co-administration of pantoprazole with nelfinavir is not recommended. Concomitant administration of omeprazole (40 mg daily) with nelfinavir (1250 mg twice daily) markedly reduced the AUC and C<sub>max</sub> for nelfinavir (by 36% and 37%, respectively) and its active metabolite M8 (by 92% and 89%, respectively) (see VIRACEPT® Product Monograph).

#### Saquinavir

Co-administration of saquinavir requires caution and monitoring, along with potential dose reduction of saquinavir, due to increased saquinavir exposure and thus the risk of saquinavir-related toxicities (see the INVIRASE® Product Monograph).

Concomitant administration of omeprazole (40 mg daily) with saquinavir/ritonavir (1000/100 mg twice daily) increased saquinavir AUC by 82% and C<sub>max</sub> by 75%.

#### Drug-Food Interactions

Consumption of food does not affect the pharmacokinetics (AUC and C<sub>max</sub>) of pantoprazole sodium. See HUMAN PHARMACOLOGY.

#### Drug-Laboratory Interactions

There have been reports of false-positive results in some urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. A confirmatory method should be considered to verify positive results.

During treatment with antisecretory drugs, chromogranin A (CgA) increases due to decreased gastric acidity. Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, RIVA-PANTOPRAZOLE treatment should be stopped 14 days before CgA measurements (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics, Pharmacodynamic Properties).

### **Other**

Generally, daily treatment with any acid-blocking medicines over a long time (e.g. longer than 3 years) may lead to malabsorption of cyanocobalamin caused by hypo- or achlorhydria. Rare cases of cyanocobalamin deficiency under acid-blocking therapy have been reported in the literature and should be considered if respective clinical symptoms are observed.

## **DOSAGE AND ADMINISTRATION**

### **Recommended Dose and Dosage Adjustment**

#### **Duodenal Ulcer**

The recommended adult dose of RIVA-PANTOPRAZOLE (pantoprazole sodium sesquihydrate) for the oral treatment of duodenal ulcer is 40 mg as pantoprazole given once daily in the morning. Healing usually occurs within 2 weeks. For patients not healed after this initial course of therapy, an additional course of 2 weeks is recommended.

#### **Gastric Ulcer**

The recommended adult oral dose of pantoprazole for the oral treatment of gastric ulcer is 40 mg given once daily in the morning. Healing usually occurs within 4 weeks. For patients not healed after this initial course of therapy, an additional course of 4 weeks is recommended.

#### **Symptomatic Gastro-esophageal reflux disease (GERD)**

The recommended adult oral dose for the treatment of symptoms of GERD, including heartburn and regurgitation, is 40 mg once daily for up to 4 weeks. If significant symptom relief is not obtained in 4 weeks, further investigation is required.

#### **Reflux Esophagitis**

The recommended adult oral dose of pantoprazole is 40 mg, given once daily in the morning. In most patients, healing usually occurs within 4 weeks. For patients not healed after this initial course of therapy, an additional 4 weeks of treatment is recommended.

Both 20 mg and 40 mg once daily have been demonstrated to be effective in the maintenance of healing of reflux esophagitis. If maintenance therapy fails when using 20 mg once daily, consideration may be given to the 40 mg daily dose as maintenance therapy.

#### **Prevention of gastrointestinal lesions induced by NSAIDs**

The recommended adult oral dose of pantoprazole is 20 mg, given once daily in the morning.

Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.

### **Missed Dose**

If a dose is forgotten, the missed dose should be taken as soon as possible unless it is close to the next scheduled dose. Two doses should never be taken at one time to make up for a missed dose; patients should just return to the regular schedule.

### **Administration**

Pantoprazole sodium is formulated as a delayed-release (enteric-coated) tablet. A whole tablet should not be chewed or crushed, and should be swallowed with fluid in the morning either before, during, or after breakfast.

### **Reconstitution:**

Not applicable.

## **OVERDOSAGE**

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

Some reports of overdosage with pantoprazole have been received. No consistent symptom profile was observed after ingestion of high doses of pantoprazole. Daily doses of up to 272 mg pantoprazole IV, and single doses of up to 240 mg IV administered over 2 minutes, have been administered and were well tolerated.

As pantoprazole is extensively protein bound, it is not readily dialyzable. In the case of overdosage with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Mechanism of Action**

Pantoprazole sodium is a specific inhibitor of the gastric H<sup>+</sup>, K<sup>+</sup>-ATPase enzyme (the proton pump) that is responsible for gastric acid secretion by the parietal cells of the stomach.

Pantoprazole is a substituted benzimidazole that accumulates in the acidic environment of the parietal cells after absorption. Pantoprazole is then converted into the active form, a cyclic sulphenamide, which binds selectively to the proton translocating region of the H<sup>+</sup>, K<sup>+</sup>-ATPase, thus inhibiting both the basal and stimulated gastric acid secretion. Pantoprazole exerts its effect in an acidic environment (pH < 3), and it is mostly inactive at higher pH. Its pharmacological and therapeutic effect is achieved in the acid-secretory parietal cells. As pantoprazole action is distal to the receptor levels, it can inhibit gastric acid secretion irrespective of the nature of the stimulus (acetylcholine, histamine, gastrin).

In long-term international studies involving over 800 patients, a 2 to 3 fold mean increase from the pre-treatment fasting serum gastrin level was observed in the initial months of treatment with

pantoprazole at doses of 40 mg per day during GERD maintenance studies and 40 mg or higher per day in patients with refractory GERD. Fasting serum gastrin levels generally remained at approximately 2 to 3 times baseline for up to 4 years of periodic follow-up in clinical trials.

### **Pharmacodynamics**

In clinical studies investigating intravenous (IV) and oral administration, pantoprazole sodium inhibited pentagastrin-stimulated gastric acid secretion. With a daily oral dose of 40 mg, inhibition was 51% on Day 1 and 85% on Day 7. Basal 24-hour acidity was reduced by 37% and 98% on Days 1 and 7, respectively.

### **Pharmacodynamic Properties:**

During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.

Available published evidence suggests that proton pump inhibitors should be discontinued 14 days prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range (see WARNINGS AND PRECAUTIONS, Interference with Laboratory Tests).

### **Pharmacokinetics**

**Absorption:** Pantoprazole is absorbed rapidly following administration of a 40 mg enteric-coated tablet. Its oral bioavailability compared to the IV dosage form is 77% and does not change upon multiple dosing. Following an oral dose of 40 mg,  $C_{max}$  is approximately 2.5 mcg/mL with a  $t_{max}$  of 2 to 3 hours. The AUC is approximately 5 mcg.h/mL. There is no food effect on AUC (bioavailability) and  $C_{max}$ .

**Distribution:** Pantoprazole is 98% bound to serum proteins. Elimination half-life, clearance and volume of distribution are independent of the dose.

**Metabolism:** Pantoprazole is almost completely metabolized in the liver. Studies with pantoprazole in humans reveal no inhibition or activation of the cytochrome P450 (CYP 450) system of the liver.

**Excretion:** Renal elimination represents the major route of excretion (about 82%) for the metabolites of pantoprazole sodium, the remaining metabolites are excreted in feces. The main metabolite in both the serum and urine is desmethylpantoprazole as a sulphate conjugate. The half-life of the main metabolite (about 1.5 hours) is not much longer than that of pantoprazole (approximately 1 hour).

Pantoprazole shows linear pharmacokinetics, i.e., AUC and  $C_{max}$  increase in proportion with the dose within the dose-range of 10 to 80 mg after both IV and oral administration. Elimination half-life, clearance and volume of distribution are considered to be dose-independent. Following repeated IV or oral administration, the AUC of pantoprazole was similar to a single dose.

## **Special Populations and Conditions**

**Pediatrics:** The safety and effectiveness of pantoprazole in children have not yet been established.

**Geriatrics:** An increase in AUC (35%) and C<sub>max</sub> (22%) for pantoprazole occurs in elderly volunteers when compared to younger volunteers after 7 consecutive days oral dosing with pantoprazole 40 mg. After a single oral dose of pantoprazole 40 mg, an increase in AUC (43%) and C<sub>max</sub> (26%) occurs in elderly volunteers when compared to younger volunteers. No dose adjustment is recommended based on age. The daily dose in elderly patients, as a rule, should not exceed the recommended dosage regimens.

**Hepatic Insufficiency:** The half-life increased to between 7 and 9 h, the AUC increased by a factor of 5 to 7, and the C<sub>max</sub> increased by a factor of 1.5 in patients with liver cirrhosis compared with healthy subjects following administration of 40 mg pantoprazole. Similarly, following administration of a 20 mg dose, the AUC increased by a factor of 5.5 and the C<sub>max</sub> increased by a factor of 1.3 in patients with severe liver cirrhosis compared with healthy subjects. Considering the linear pharmacokinetics of pantoprazole, there is an increase in AUC by a factor of 2.75 in patients with severe liver cirrhosis following administration of a 20 mg dose compared to healthy volunteers following administration of a 40 mg dose. Thus, the daily dose in patients with severe liver disease should, as a rule, not exceed 20 mg pantoprazole.

**Renal Insufficiency:** In patients with severe renal impairment, pharmacokinetic parameters for pantoprazole were similar to those of healthy subjects. No dosage adjustment is necessary in patients with renal impairment or in patients undergoing hemodialysis, as the difference in AUCs between patients who are dialyzed and those who are not is 4%.

## **STORAGE AND STABILITY**

Store in a dry place at room temperature (between 15°C and 30°C).

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

### **Dosage Forms**

RIVA-PANTOPRAZOLE (pantoprazole sodium sesquihydrate) is available for oral administration as delayed-release (enteric-coated) tablets of 40 mg.

### **Composition**

RIVA-PANTOPRAZOLE 40 mg tablets are yellow, oval tablets and contain 40 mg pantoprazole (45.1 mg pantoprazole sodium sesquihydrate).

The nonmedicinal ingredients are as follows: Calcium stearate, cellulose microcrystalline, crospovidone, ferric oxide black, ferric oxide red, ferric oxide yellow, hydroxypropylcellulose, hypromellose, macrogol, methacrylic acid – ethyl acrylate copolymer, polysorbate 80, ponceau 4R aluminium lake, povidone, quinoline yellow aluminium lake, shellac, silica-colloidal anhydrous, sodium carbonate anhydrous, sodium laurilsulfate, titanium dioxide, triethyl citrate.

## **Packaging**

40 mg: Available in bottles containing 500 tablets.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance


Proper name: pantoprazole sodium sesquihydrate

Chemical name: Sodium-[5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)-methyl]-sulfinyl]- 1H-benzimidazolide sesquihydrate

Molecular formula: C<sub>16</sub>H<sub>14</sub>F<sub>2</sub>N<sub>3</sub>NaO<sub>4</sub>S x 1.5 H<sub>2</sub>O

Molecular mass: 432.4 g/mole

Structural formula:



#### Physicochemical properties:

Physical description: White to off-white powder

Solubilities in common solvents: Pantoprazole sodium sesquihydrate is freely soluble in ethanol and water, and practically insoluble in hexane.

pH: 1% aqueous solution: 10.05  
10% aqueous solution: 10.85

pKa: 3.94 pyridine;  
8.23 benzimidazole

## CLINICAL TRIALS

### Comparative Bioavailability Studies

Two comparative blind, randomized, single-dose, 2-way, crossover bioavailability studies were performed using healthy, non-smoking, male, human volunteers under fasting conditions and fed conditions. The rate and extent of absorption of pantoprazole following a single 40 mg (1x40 mg tablet) oral dose of RIVA-PANTOPRAZOLE delayed-release tablet and Pantoloc® enteric-coated tablet (Reference) were measured and compared. The results from measured data are summarized as follows:

### Fasting Study

Thirty-two volunteers were enrolled in the study, and 30 subjects completed the clinical phase of the study. The statistical and pharmacokinetic analyses were performed based on 28 (between ages of 22 to 53 with a median of 33 years old) subjects.

Pantoprazole (1 x 40 mg) From measured data fasted Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test* Pantoprazole sodium sesquihydrate	Reference† Pantoloc®	% Ratio of Geometric Means#	90% Confidence Interval#
AUC <sub>0-t</sub> (ng·h/mL)	3871.33 4168.21 (39.91)	3877.32 4339.87 (44.28)	99.85	87.31-114.18
AUC <sub>0-inf</sub> (ng·h/mL)	3917.47 4218.64 (40.08)	3916.62 4382.06 (44.59)	100.02	87.84-113.89
C <sub>max</sub> (ng/mL)	2032.85 2192.65 (39.68)	2312.06 2534.50 (32.29)	87.92	73.28-105.49
T <sub>max</sub> <sup>§</sup> (h)	3.17 (38.72)	2.88 (46.88)		
T <sub>½</sub> <sup>§</sup> (h)	1.20 (30.63)	1.17 (28.84)		

\*Pantoprazole 40 mg tablets manufactured for Laboratoire Riva Inc.

† Pantoloc®, Solvay Pharma Inc., Canada /Altana Pharma AG, Germany Purchased in Canada.

§ Expressed arithmetic mean (CV%) only.

# Based on least-squares mean estimates.

## Fed Study

Fifty volunteers were enrolled in the study, and 44 subjects completed the clinical phase of the study. The statistical and pharmacokinetic analyses were performed based on 44 (between ages of 22 to 55 with a median of 32 years old) subjects.

Pantoprazole (1 x 40 mg) From measured data Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test <sup>*</sup> Pantoprazole sesquihydrate sodium	Reference <sup>†</sup> Pantoloc®	% Ratio of Geometric Means <sup>#</sup>	90% Confidence Interval <sup>#</sup>
AUC <sub>0-t</sub> (ng·h/mL)	2804.27 3459.55 (53.57)	2802.87 3606.46 (48.09)	100.05	91.78-109.07
AUC <sub>0-inf</sub> (ng·h/mL)	3433.05 3819.01 (47.51)	3458.53 3792.86 (44.13)	99.27	95.34-103.36
C <sub>max</sub> (ng/mL)	1859.38 2083.24 (35.12)	2010.82 2289.90 (28.92)	92.48	85.54-99.98
T <sub>max</sub> <sup>§</sup> (h)	8.85 (56.89)	8.66 (49.40)		
T <sub>½</sub> <sup>§</sup> (h)	1.28 (38.00)	1.32 (34.43)		

\*Pantoprazole 40 mg tablets manufactured for Laboratoire Riva Inc.

†Pantoloc®, Solvay Pharma Inc., Canada /Altana Pharma AG, Germany Purchased in Canada.

§ Expressed arithmetic mean (CV%) only.

# Based on least-squares mean estimates.

### **Symptomatic gastro-esophageal reflux disease**

In a US placebo-controlled study involving 538 patients, a significantly greater proportion of patients taking pantoprazole sodium 40 mg experienced complete relief of daytime and night time heartburn and the absence of regurgitation starting from the first day of treatment compared with placebo. Patients taking pantoprazole sodium consumed significantly fewer antacid tablets per day than those taking placebo.

In a second US study involving 215 patients, a significantly greater proportion of the patients in the pantoprazole sodium treatment groups experienced complete relief of night time heartburn and regurgitation starting on the first day and of daytime heartburn on the second day compared with those taking nizatidine 150 mg twice daily. Patients taking pantoprazole sodium consumed significantly fewer antacid tablets per day than those taking nizatidine.

### **Prevention of gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs (NSAIDs)**

Two pivotal studies have been conducted to investigate the effect of pantoprazole sodium in the prevention of the occurrence of endoscopically evident gastrointestinal lesions in patients who, at the start of the study do not present with endoscopically evident gastrointestinal lesions but who have increased risk to develop NSAID-associated upper gastrointestinal lesions.

The following efficacy criteria were used in the studies:

- a. Therapeutic failure — Defined as “detection of peptic ulcer and/or more than ten erosions and/or petechiae in the stomach or duodenum, and/or, reflux esophagitis, and/or, adverse event (assessed as ‘likely’ or ‘definitely’ related to the study medication), and/or gastrointestinal symptoms leading to premature termination”.
- b. Endoscopic failure — Defined as “detection of peptic ulcer, and/or, more than ten erosions/petechiae in the stomach or duodenum, and/or, reflux esophagitis”.
- c. Symptomatic failure — Defined as the occurrence of severe gastrointestinal symptoms such as heartburn, epigastric pain, retrosternal feeling of tightness, abdominal pain, eructation of air, acid eructation, pain on swallowing, nausea, retching, vomiting (often collectively referred to as dyspeptic symptoms) including at least “likely” related adverse events of severe intensity concerning the gastrointestinal tract.

The results of the studies in patients who require continuous intake of NSAIDs and who have increased risk to develop NSAID-associated gastrointestinal lesions are presented in the table below.

**Effect of Pantoprazole Sodium in Prevention of Occurrence of Endoscopically Evident Gastrointestinal Lesions in Patients Requiring Continuous Intake of NSAIDs and Who Have Increased Risk to Develop NSAID-Associated Upper Gastrointestinal Lesions**

In remission with regard to Efficacy Criteria:	Time interval (months)	Study 1; Pantoprazole 20 mg od (P20) vs pantoprazole 40 mg od (P40) vs omeprazole 20 mg od (O20)			Study 2; Pantoprazole 20 mg od (P20) vs misoprostol 200 mcg bid (M200)		
		Remission Rate (%)			Remission Rate (%)		
		P20 n = 196	P40 n = 199	O20 n = 200	P20 n = 257	M200 n = 258	p value P20 vs M200
Therapeutic failure	0-3	94.2	97.2	93.8	92.5	78.7	<0.001
	0-6	89.8	93.1	88.7	89.3	70.3	<0.001
Endoscopic failure	0-3	95.9	98.9	96.0	98.0	95.3	0.16
	0-6	91.4	95.3	93.3	94.7	85.7	0.005
Symptomatic failure	0-3	98.8	100	98.8	98.5	92.3	0.004
	0-6	98.1	100	98.1	98.5	91.7	0.002

“In remission” is defined as patients who did not have any of the findings (e.g. “therapeutic failure”, “endoscopic failure”, or symptomatic failure” after 6 months).

Remission rates were obtained by subtracting failures from 100%.

In a six-month study involving 595 patients requiring continuous intake of NSAIDs, treatment with pantoprazole 20 mg od was equivalent to the treatment with pantoprazole 40 mg od and omeprazole 20 mg od in this indication.


In a second six-month study involving 515 patients requiring continuous intake of NSAIDs, pantoprazole 20 mg was not only equivalent but statistically significantly superior to treatment with misoprostol 200 mcg bid with respect to symptomatic and endoscopic findings.

### **Prevention of Relapse of Reflux Esophagitis**


The long-term maintenance of healing of erosive esophagitis was assessed in two U.S. randomised, double-blind, parallel-group, active controlled studies. Eligible patients in both studies had a recent history of grade II or III (Hetzell-Dent) erosive esophagitis, and endoscopically demonstrated healing. Both studies used as the primary endpoint endoscopically demonstrated recurrence (assessed at month 1, 3, 6 and 12) of erosive esophagitis (‘relapse’). Gelusil antacid tablets were to be taken as needed for symptomatic relief after 5 or more minutes of retrosternal pain, acid regurgitation, or dysphagia, but not within 1 hour before or after taking study medication. Ad hoc endoscopies were performed when symptoms of GERD occurred for more than 3 consecutive days. As the primary analysis Kaplan Meier’s method was performed, whereas the discrete analysis was secondary.

In the US studies, the results of Kaplan-Meier’s analyses showed that the cumulative proportion of relapse over time was dose-related for the pantoprazole treatment groups. The cumulative proportion of relapse at 12 months for patients treated with pantoprazole 20 mg and pantoprazole 40 mg exhibited a statistically significant difference in the pooled data (p-value=0.001) and in the data of one of the studies (3001A1-302-US: p-value=0.012, 3001A1-303-US p-value=0.052) (p-values adjusted for pairwise comparison).

Kaplan-Meier plot; 3001A1-302-US



Kaplan-Meier plot; 3001A1-303-US



In the discrete analysis of the pooled results of the two U.S. studies, 40 mg was significantly ( $p$ -value=0.004) more effective in the maintenance of healed erosive esophagitis compared to 20 mg (see following table).

**Long-term Maintenance of Healing of Erosive Esophagitis: Proportion of Patients Who Relapse in Individual Studies and Pooled Studies at 12 months. U.S. Studies**

	Pantoprazole 20 mg n/N(%)	Pantoprazole 40 mg n/N(%)	Ranitidine 150 mg n/N(%)
<b>Study 3001A1-302-US</b>			
Month 1	11/86(12.8)*	1/78(1.3)*	32/84(38.1)
Month 3	17/77(22.1)*	5/76(6.6)*	41/81(50.6)
Month 6	21/77(27.3)*	8/70(11.4)*	47/77(61.0)
Month 12	25/75(33.3)*	10/64(15.6)* <sup>a</sup>	52/76(68.4)
<b>Study 3001A1-303-US</b>			
Month 1	11/87(12.6)*	8/93(8.6)*	37/92(40.2)
Month 3	21/80(26.3)*	10/88(11.4)*	45/83(54.2)
Month 6	24/75(32.0)*	12/85(14.1)*	51/79(64.6)
Month 12	25/73(34.2)*	15/78(19.2)*	52/78(66.7)
<b>Pooled data</b>			
Month 12	50/148(33.8)*	25/142(17.6)* <sup>a</sup>	104/154(67.5)

\*Statistically significant between treatment and ranitidine at 0.05 level; <sup>a</sup> Statistically significant between pantoprazole 40 mg and 20 mg with adjusted p-value (Holm procedure). Mean age 302-US 49.2 years, 303-US 48.95 years, 302-US: 28% female/72% male 303-US: 38% female/62% male, 302-US: 3.9% black, 4.1 %Hispanic, <1% Asian, 91% white, <1% other, US-303: 6.4% black, 6.4% Hispanic, <1% Asian, 86% white, <1% other.

Additionally, long-term maintenance of healing of erosive esophagitis was assessed in two European, randomized, double-blind, parallel-group non-inferiority studies. Eligible patients in both studies had a recent history of grade II or III (Savary-Miller) erosive esophagitis, and endoscopically demonstrated healing. Both studies used as the primary endpoint endoscopically demonstrated recurrence of erosive esophagitis ('relapse'). Pantoprazole 40 mg is non-inferior to pantoprazole 20 mg which means patients who were treated with pantoprazole 40 mg showed no less reduction in the proportion of relapse at 12 months compared to pantoprazole 20 mg.

**Long-term maintenance of healing of erosive esophagitis: proportion of patients who relapse in individual studies and pooled studies at 12 months. European studies\***

Study	Month	Relapse rates (%)		Diff. Between Treatment and 95% CI (%)
		40 mg Pantoprazole	20 mg Pantoprazole	
FK3028	12	39/174 (22)	45/174 (26)	-3.5 (-12.4;5.5)
FK3033	12	30/151 (20)	49/161 (30)	-10.6 (-20;-1)
Pooled	12	69/325 (21)	94/335 (28)	-6.8 (-13.4;-0.3)

Mean age FK3028 56 years, FK3033 50 years, FK3028 35% female/65% male, FK3033: 28% female/72% male.

\* These studies were performed between 1993-1997.

## DETAILED PHARMACOLOGY

### ANIMAL PHARMACOLOGY

#### Pharmacodynamics:

*In vivo*, pantoprazole produced marked and long-lasting inhibition of basal and stimulated gastric acid secretion with median effective dose ( $ED_{50}$ ) values ranging from 0.2-2.4 mg/kg in rats and dogs. In addition to the administration of single doses, pantoprazole has been tested upon repeated oral administration (e.g. during 24-h pH-metry in dogs performed under pentagastrin stimulation). While a dose of 1.2 mg/kg did not significantly elevate pH on Day 1, pH rose to

values between 4 and 7 after a 5-day dosing regimen. This effect was no longer observed 18 hours after the last drug administration. In various gastric ulcer models in the rat, pantoprazole showed antiulcer activity.

In parallel to the profound inhibition of gastric acid secretion, pantoprazole induced a dose-dependent increase in serum gastrin levels up to values above 1000 pg/mL from a control level of about 100 pg/mL. As a consequence of persisting hypergastrinemia in rats after high/doses of pantoprazole, hyperplastic changes were observed in the fundic mucosa with an increased density of enterochromaffin-like (ECL) cells. These changes were reversible during drug-free recovery periods.

In a battery of standard high-dose pharmacology tests, no influence of pantoprazole was detected on the central and peripheral nervous system. In conscious dogs as well as anesthetized cats receiving single IV doses up to 10 mg/kg pantoprazole, no consistent changes with respect to respiratory rate, ECG, EEG, blood pressure and heart rate were observed. Higher doses led to modest and transient reductions in blood pressure and variable changes in heart rate. No influence of pantoprazole was found on renal function and on autonomic functions, such as pancreatic and bile secretion, gastrointestinal motility and body temperature.

No consistent changes in the effects of ethanol, pentobarbitone, or hexobarbitone were induced by pantoprazole; only doses over 300 mg/kg prolonged the effects of diazepam.

### **Pharmacokinetics:**

#### **Absorption and Distribution**

Pantoprazole is absorbed rapidly in both rat and dog. Peak plasma levels are attained within 15 to 20 minutes in the rat and after about 1 hour in the dog. Oral bioavailability is 33% in the rat and 49% in the dog. Following absorption, autoradiography and quantitative tissue distribution experiments have shown that pantoprazole is rapidly distributed to extravascular sites. Following administration of pantoprazole, distribution of radioactivity in the blood and most organs is found to be uniform initially. After 16 hours, radiolabelled pantoprazole is predominantly detected in the stomach wall. After 48 hours, all the administered radioactivity is found to have been excreted. Penetration of the blood-brain barrier by radiolabelled pantoprazole is very low. Protein binding in the rat and dog is 95% and 86%, respectively.

#### **Metabolism and Excretion**

Pantoprazole is extensively metabolized. Oxidations and reductions at different sites of the molecule, together with Phase II reactions (sulfation and glucuronidation) and combinations thereof result in the formation of various metabolites. In rats and dogs, 29-33% of a pantoprazole dose is excreted as urinary metabolites, and the remainder as biliary/fecal metabolites. Almost no parent compound can be found in the excreta.

Mammoglandular passage and transplacental transport has been investigated in the rat using radiolabelled pantoprazole. A maximum of 0.23% of the administered dose is excreted in the milk. Radioactivity penetrates the placenta with 0.1-0.2% of the dose /g fetal tissue on the first day after oral administration.

## HUMAN PHARMACOLOGY

### **Pharmacodynamics:**

Pantoprazole is a potent inhibitor of gastric acid secretion. This was demonstrated with pantoprazole by use of a gastric acid aspiration technique as well as by continuous intragastric pH monitoring. Using the aspiration technique it was also shown that pantoprazole caused a dose-dependent reduction of secreted gastric acid volume.

**Table 1: Percent Inhibition of Pentagastrin-Stimulated Acid Output (PSAO) in Healthy Volunteers Following Single Oral Doses of Pantoprazole vs. Placebo During 4 to 7 Hours Post Dosing.**

Dose	Mean % Inhibition of PSAO
6 mg	13%
10 mg	24%
20 mg	27%
40 mg	42%
60 mg	54%
80 mg	80%
100 mg	82%

With 40 mg administered orally, effective inhibition of gastric acid secretion was achieved. Pantoprazole 40 mg was significantly superior to standard H<sub>2</sub>-blocker therapy (300 mg ranitidine at night) with regard to median 24-hour and daytime pH; however, not for nighttime measurements.

**Table 2: Effects of One Week Oral Treatment in Healthy Volunteers With Placebo, Pantoprazole 40 mg in the Morning, and Standard Ranitidine Therapy With 300 mg in the Evening**

Time of Day		Median pH	
	Placebo	Pantoprazole 40 mg	Ranitidine 300 mg
08.00-08.00 (24h)	1.6	4.2*	2.7
08.00-22.00 (Day time)	1.8	4.4*	2.0
22.00-08.00 (Night time)	1.3	3.1	3.7

\* p<0.05 vs ranitidine

Increasing the once daily dose from 40 mg to 80 mg pantoprazole did not result in a significantly higher median 24-hour pH.

**Table 3: Effect of Oral Pantoprazole in Healthy Volunteers on Median 24-hour pH on Day 7 (40 vs 80 mg).**

40 mg	80 mg	
3.8	3.85	n.s.

n.s.=not significant

Hence, once daily administration of 40 mg pantoprazole should be sufficient for the treatment of most patients with acid-related diseases.

### **Pharmacokinetics:**

The absolute bioavailability of the pantoprazole tablet is 77%. Maximum serum concentrations of pantoprazole are reached within approximately 2.5 hours after oral intake. Following a dose of 40 mg, mean maximum serum concentrations of approximately 2 mcg/mL and 3 mcg/mL are

reached after 2 to 3 hours. There is no food effect on AUC (bioavailability) and  $C_{max}$ . However, time to reach maximum serum concentrations is slightly increased when the drug is given together with a high caloric breakfast. Taking into account the long duration of action of pantoprazole, which by far exceeds the time period over which serum concentrations are measurable, this observed variation in  $t_{max}$  is considered to be of no clinical importance.

Pantoprazole is approximately 98% bound to serum protein.

Despite its relatively short elimination half-life of approximately 1 hour, the antisecretory effect increases during repeated once daily administration, demonstrating that the duration of action markedly exceeds the serum elimination half-life. This means that there is no direct correlation between the serum concentrations and the pharmacodynamic action.

Morning administration of pantoprazole was significantly superior to evening dosing with regard to 24 hour intragastric pH, hence morning dosing should be recommended for the treatment of patients. Since the intake of the drug before a breakfast did not influence  $C_{max}$  and AUC, which characterize rate and extent of absorption, no specific requirements for intake of pantoprazole in relation to breakfast are necessary.

Pantoprazole undergoes metabolic transformation in the liver. Approximately 82% of the oral dose is removed by renal excretion, and the remainder *via* feces. The main serum metabolites (M1-M3) are sulphate conjugates formed after demethylation at the pyridine moiety, the sulphoxide group being either retained (M2, main metabolite), or oxidized to a sulphone (M1), or reduced to a sulphide (M3). These metabolites also occur in the urine (main metabolite M2). Conjugates with glucuronic acid are also found in the urine.

## **TOXICOLOGY**

### **ACUTE TOXICITY**

In acute toxicity studies in mice the mean lethal dose ( $LD_{50}$ ) values for pantoprazole were found to be around 390 mg/kg bodyweight for IV administration and around 700 mg/kg bodyweight for oral administration.

In the rat the corresponding values were around 250 mg/kg for IV administration and >1000 mg/kg for oral administration.

Acute toxicity studies were conducted on B8810-044, the major degradation product of pantoprazole. The approximate  $LD_{50}$  values for mice (119-167 mg/kg) and rats (73-82 mg/kg) were lower than those for pantoprazole itself, after intravenous injection, but the toxic symptoms were similar to those noted for the drug. A 4-week repeat dose study was also conducted using this degradation product using the intravenous route in rats. Rats received 5 and 25 mg of B8810-044/ kg, while a comparison group received 25 mg/kg of pantoprazole. Muscle twitches were observed immediately after injection in rats receiving 25 mg/kg of the degradation product, but not in the pantoprazole-treated animals. Otherwise the compounds were comparable.

**Table 4: Acute Toxicity Studies of Pantoprazole**

SPECIES	SEX	ROUTE	ca. LD <sub>50</sub> *
			(mg/kg)
Mouse	M	PO	>1000
	F	PO	747
Mouse	M	IV	399
	F	IV	395
Rat	M	PO	1343
	F	PO	1037
Rat	M	IV	330
	F	IV	343
Dog	M/F	PO	300-1000**
	M/F	IV	150-300

\* Doses refer to the sodium salt administered in solution

\*\* sodium salt as dry powder in gelatine capsules

The symptoms seen after lethal oral or IV doses were similar in rats and mice: the animals displayed ataxia, reduced activity, hypothermia and prostration. Surviving animals recovered uneventfully. Salivation, tremor, lethargy, prostration and coma were seen in dogs at lethal oral doses, with death occurring on the following day. Ataxia, tremor and a prone position were noted at sublethal oral and IV doses, but the survivors recovered quickly and appeared fully normal after the 2-week observation period.

## CHRONIC TOXICITY

Daily oral doses of pantoprazole in 1- and 6-month SD rat repeated-dose studies were 1, 5, 20, and 500 mg/kg and 0.8, 4, 16 and 320 mg/kg, respectively; doses for a 1 month rat IV study were 1, 5, and 30 mg/kg.

A 12-month toxicity study in SD rats was conducted using daily oral doses of 5, 50, and 300 mg/kg. Daily oral doses in 1- and 6-month (beagle) dog studies were 7.5, 15, 30, and 100 mg/kg and 5, 15, 30, and 60 mg/kg respectively. In a 12-month oral study in dogs, 2.5, 15, and 60 mg/kg were administered daily.

Hypergastrinemia was dose-related and was observed at all doses investigated in the studies mentioned above, but was reversible upon cessation of treatment. Drug-related effects on the stomach included increased stomach weights and morphologic changes of the mucosa. In the 6-month rat study, increased stomach weight and some cellular changes were detected at all doses. In the 1-month rat study, gastric changes were detected at 5 mg/kg but not at 1 mg/kg. In dogs, increased stomach weight was observed at all doses studied. There were no gastric cellular changes detected at oral doses of 7.5 or 5 mg/kg in the 1- and 6-month dog studies, respectively. In both species, most gastric effects were reversible after a 4- or 8-week recovery period. Hypergastrinemia and gastric changes were considered to be the consequence of the pharmacological action of the compound, namely prolonged and profound inhibition of acid secretion.

Increased liver weight in the rat experiments was considered to be a consequence of the induction of hepatic drug metabolizing systems and was found to be associated with

centrilobular hepatocellular hypertrophy at 320 mg/kg in the 6-month study and at 50 and 300 mg/kg after 12 months of treatment. Increased liver weights were also detected at a dose of 16 mg/kg in male rats in the 6-month study and at 500 mg/kg, but not 20 mg/kg, in the 1-month study. Increased liver weight was noted in male dogs of all dose groups in the 1-month study, though only at 100 mg/kg in females on the same study. Both males and females had increased liver weights after 6 months administration of 30 or 60 mg/kg, but not of 15 mg/kg. In the 12-month study, liver weights were increased only in the female dogs dosed with 60 mg/kg. There were no hepatic lesions that correlated with increased liver weight in the dog studies. In dogs, the increase in liver weight was attributed to an activation of hepatic drug metabolizing systems as mentioned for rats.

Thyroid activation in animal experiments is due to the rapid metabolism of thyroid hormones in the liver and has been described in a similar form for other drugs. Thyroid weights were increased in both sexes at 500 mg/kg in the 1-month rat study and at 320 mg/kg in the rat 6-month study. Thyroid follicular cell hypertrophy was noted in females at these doses, in rats treated with 50 and 300 mg/kg in the 12-month study and also in a few females at 16 mg/kg in the 6-month study. There were no thyroid effects in rats at or below an oral dose of 5 mg/kg even after 1 year. In the dog, no effects were seen on the thyroid after 4 weeks. Only slight, but not dose-dependent, increases in thyroid weights were seen after 6 months, but no changes were observed histologically. In the 12-month study, the relative thyroid weights in the 60 mg/kg group were only slightly higher than those of the control dogs, and changes were detected histologically in only a few animals under 15 and 60 mg/kg. In both species, changes were reversible.

Increased serum cholesterol values were noted in all groups in the 6- and 12-month dog studies and in all groups in the 12 month rat study. The increases were slight and were reversible after cessation of treatment.

In dog studies, oral doses of pantoprazole of 15 mg/kg or above caused a transient pulmonary edema in a proportion of naive dogs during the first week of drug administration. Pulmonary edema caused death in a few dogs after repeated oral doses of 15 mg/kg or above. There is strong evidence that the pulmonary toxicity is due to a thiol metabolite which does not occur in man. No evidence of pulmonary edema was detected in dogs at an oral dose of 7.5 mg/kg nor at 60 mg/kg when administered daily for 6 or 12 months after a 1 week dose escalation phase.

## **CARCINOGENICITY**

Three carcinogenicity studies had been conducted with pantoprazole:

- A 24 month oral study was conducted at doses of 0.5, 5, 50 and 200 mg/kg/day in SD rat.
- A 24 month oral study was conducted at doses of 5, 15 and 50 mg/kg/day in Fischer-344 rat.
- A 24 month oral study was conducted at doses of 5, 25 and 150 mg/kg/day in B6C3F1 mouse.

Pantoprazole, dissolved in distilled water, was administered once a day by oral gavage to groups of 50 male and 50 female B6C3F1 mice at doses of 5, 25, or 150 mg/kg. An identical control group was dosed with distilled water (pH 10), while a second identical control group received no treatment at all. In the first rat study, pantoprazole was administered once a day by oral gavage to

groups of 70 male and 70 female SD rats at doses of 0.5, 5, 50, and 200 mg/kg. A control group of 70 males and 70 females received the vehicle. In the second rat study, pantoprazole was administered once a day by oral gavage to groups of 50 male and 50 female Fischer-344 rats at doses of 5, 15, and 50 mg/kg. A control group of 50 males and 50 females received the vehicle, while another group remained untreated.

In the first 2 year carcinogenicity study in rats, which corresponds to a lifetime treatment for rats, neuroendocrine neoplasms were found in the stomach at doses of 50 mg/kg/day and above in males and at 0.5 mg/kg/day and above in females. Tumour formation occurred late in the life of the animals (only after 17 months treatment), whereas no tumours were found in rats treated with an even higher dose for 1 year. The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated, and it is considered to be due to high levels of serum gastrin observed in the rat during chronic treatment. In the second rat carcinogenicity study, neuroendocrine cell tumours in the stomach were found in all treated female groups and in the male 15 and 50 mg/kg groups. No metastases from any gastric neuroendocrine cell tumours were detected.

ECL-cell neoplasms were not observed in either the carcinogenicity study in the mouse (24 months) or in the chronic studies in the dog. In clinical studies, where pantoprazole was administered at doses up to 80 mg, ECL-cell density remained almost unchanged.

Microscopy of the rat (first carcinogenicity study) and mouse tissues gave evidence for an increase in liver tumours. In the rat experiment, the incidence of benign liver tumours in the 50 and 200 mg/kg groups and the incidence of hepatocellular carcinoma was increased in the males and females of the 200 mg/kg group. There was a slightly higher incidence of hepatocellular adenomas and carcinomas in the female mice of the 150 mg/kg group than in either of the 2 control groups. Other changes in the liver morphology were present as well. Centrilobular hepatocellular hypertrophy increased in incidence and severity with increasing dose, and hepatocellular necrosis was increased in the highest dose in the rat studies and in the mouse study. Hepatocellular tumours are common in mice, and the incidence found for the female 150 mg/kg group was within historical control ranges for this strain. The liver tumour incidences in rats treated with 50 mg/kg and in the male rats treated with 200 mg/kg were also within historical control incidences for the rat. These tumours occurred late in the life of the animals and were primarily benign. The nongenotoxic mechanism of rodent liver tumour formation after prolonged treatment with pantoprazole is associated with enzyme induction leading to hepatomegaly and centrilobular hypertrophy and is characterized by tumour induction in low incidences at high doses only. As pantoprazole acts in a similar fashion to phenobarbital, causing reversible centrilobular hepatocellular hypertrophy and enzyme induction in short-term studies, it is probable that the mechanism of action for induction of the liver tumours seen in long-term rodent studies is also the same. Hepatocellular tumours at high doses in rodents are not indicative of human carcinogenic risk.

A slight increase in neoplastic changes of the thyroid was observed in rats receiving pantoprazole at 200 mg/kg/day. The incidences of these tumours were within the historical control ranges for this rat strain. No thyroid neoplasms were observed in the 12-month study. The no-effect dose for both male and female rats is 50 mg/kg, which is 100 times the most commonly used human

dose (i.e. 40 mg dose). The effect of pantoprazole on the thyroid is secondary to the effects on liver enzyme induction, which lead to enhanced metabolism of thyroid hormones in the liver. As a consequence, increased TSH is produced, which has a trophic effect on the thyroid gland. Clinical studies have demonstrated that neither liver enzyme induction nor changes in thyroid hormonal parameters occur in man after therapeutic doses of pantoprazole.

Tumours induced in rats and mice by pantoprazole were the result of nongenotoxic mechanisms which are not relevant to humans. Tumours were induced in rodents at dosages that provide higher exposure than with human therapeutic use. Based on kinetic data, the exposure to pantoprazole in rats receiving 200 mg/kg was 22.5 times higher than that found in humans receiving 40 mg oral doses. In mice receiving 150 mg/kg, exposure to pantoprazole was 2.5 times higher than that in humans.

## MUTAGENICITY

Pantoprazole was studied in several mutagenicity studies: Pantoprazole was found negative in the Ames test, an *in vivo* chromosome aberration assay in rat bone marrow, a mouse lymphoma test, two gene mutation tests in Chinese hamster ovary cells *in vitro*, and two micronucleus tests in mice *in vivo*. Pantoprazole was found positive in three of four chromosome aberration assays in human lymphocytes *in vitro*. The *in vitro* tests were conducted both in the presence and absence of metabolic activation. The potential of pantoprazole to induce DNA repair synthesis was tested negative in an *in vitro* assay using rat hepatocytes. In addition, a rat liver DNA covalent binding assay showed no biologically relevant binding of pantoprazole to DNA.

In addition, two *in vitro* cell transformation assays using different cell types were performed to aid in the interpretation of the rodent carcinogenicity studies; in neither test did pantoprazole enhance the morphologic transformation of the cell types used.

A bacterial mutation assay conducted with the degradation product B8810-044, gave no indication of a mutagenic potential.

## REPRODUCTION AND TERATOLOGY

Pantoprazole was not teratogenic to rats or rabbits at doses up to 450 and 40 mg/kg/day (gavage), 20 and 15 mg/kg/day (IV injection), respectively.

Treatment of male rats with pantoprazole up to 500 mg/kg PO for 127 days did not affect fertility. Treatment of pregnant rats induced dose-dependent fetotoxic effects: increased pre- and postnatal deaths (450 mg/kg/day), reduced fetal weight and delayed skeletal ossification (150 mg/kg/day), and reduced pup weight (15 mg/kg/day). These results may be explained by maternal toxicity of pantoprazole at high dose and/or placental transfer of pantoprazole.

Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentration of pantoprazole in the fetus is increased shortly before birth regardless of the route of administration.

In humans, there are no adequate or well-controlled studies with the use of pantoprazole during pregnancy.

## REFERENCES

1. Escourrou J, Deprez P, Saggioro A, et al. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux esophagitis. *Aliment Pharmacol Ther* 1999 Nov; 13 (11): 1481-91.
2. Gugler R, Hartmann M, Rudi J, Brod I, Huber R, Steinijans VW, Bliesath H, Wurst W, Klotz U. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man; *Br J Pharmacol* 1996;42(2):249-252.
3. Hanauer G, Graf U, Meissner T. *In vivo* cytochrome P-450 interactions of the newly developed  $H^+$   $K^+$ -ATPase inhibitor Pantoprazole (BY1023/SK&F96022) compared to other antiulcer drugs; *Meth Find Exp Clin Pharmacol* 1991;13(1):63-67.
4. Hannan A, Weil J, Broom C, Walt RP. Effects of oral Pantoprazole on 24 hour intragastric acidity and plasma gastrin profiles; *Aliment Pharmacol Ther* 1992; 6:373-380.
5. Hartmann M, Theiß U, Bliesath H, Kuhn I, Lühmann R, Huber R, Wurst W, Postius S, Lücker P. 24 h intragastric pH following oral intake of Pantoprazole and omeprazole; *Hellenic J. Gastroenterol* 1992;5(suppl.):112 (A No. 451).
6. Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, Zech K. Pharmacokinetic of pantoprazole in man; *Internal J Clin Pharmacol Therap* 1996;34:185-194.
7. Judmaier G, Koelz H.R. Pantoprazole-duodenal ulcer-study group; Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer; *Aliment Pharmacol Ther* 1994;8:81-86.
8. Kliem V, Bahlmann J, Hartmann M, Huber R, Lühmann R, Wurst W. Pharmacokinetics of pantoprazole with end-stage renal failure. *Nephrol Dial Transplant* 1998;13:1189-1193.
9. Kohl B. et al. ( $H^+$ ,  $K^+$ ) -ATPase inhibiting-2-[(2-pyridylmethyl)suifinyl] benzimidazoles. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of Pantoprazole as a clinical candidate; *J Medicinal Chem* 1992;35:1049-1057.
10. Kovacs TOG, DeVault K, Metz D, et. al. Pantoprazole prevents relapse of healed erosive esophagitis more effectively than ranitidine in gastroesophageal reflux disease patients. *Am J Gastroenterol* 1999; 94 (9): 2590 (A No. 53).
11. Mossner J, Holscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial; *Aliment Pharmacol Ther* 1995;9:321-326.

12. Müller P, Simon B, Khalil H, Lühmann R, Leucht U, Schneider A. Dose-range finding study with the proton pump inhibitor Pantoprazole in acute duodenal ulcer patients; Z Gastroenterol 1992;30:771-775.
13. Plein K, Hotz J, Wurzer H, et al. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000 Apr; 12 (4): 425-32.
14. Pue MA, Laroche J, Meineke I, de Mey C. Pharmacokinetics of Pantoprazole following single intravenous and oral administration to healthy male subjects; Eur J Clin Pharmacol 1993 ;44:575-578.
15. Sachs G. Gastric H<sub>+</sub>K<sup>+</sup>-ATPase as therapeutic target; Ann Rev Pharmacol Toxicol 1988;28:269-284.
16. Schulz H-U, Hartmann M, Steinijans VW, Huber R, Luhrmann B, Bliesath H, Wurst W. Lack of influence of Pantoprazole on the disposition kinetics of theophylline in man; Int J Clin Pharmacol Ther 1991 ;29(9):369-375.
17. Simon B, Müller P, Bliesath H, Lühmann R, Hartmann M, Huber R, Wurst W. Single intravenous administration of the H<sub>+</sub>,K<sup>+</sup>-ATPase inhibitor BY1023/SK & F96022 - inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man; Aliment Pharmacol Therap 1990a;4:239-245.
18. Simon B, Müller P, Hartmann M, Bliesath H, Lühmann R, Huber R, Bohnenkamp W, Wurst W. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H<sub>+</sub>,K<sup>+</sup>-ATPase inhibitor Pantoprazole (BY1023/SK&F96022) in healthy volunteers; Z Gastroenterol 1990;28:443- 447.
19. Simon B, Müller P, Marinis E, Lühmann R, Huber R, Hartmann M, Wurst W. Effect of repeated oral administration of BY1023/SK&F96022 - a new substituted benzimidazole derivative - on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man; Aliment Pharmacol Therap 1990c;4:373-379.
20. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW. Lack of pantoprazole drug interactions in man: an updated review; Internal J Clin Pharmacol Therap 1996;34:S31-S50.
21. Takeda Canada Inc., Product Monograph for Pantoloc, Date of Revision: September 13, 2017, Control: 206282.

## PART III: PATIENT MEDICATION INFORMATION

### READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

#### **Pr RIVA-PANTOPRAZOLE**

Pantoprazole Delayed-Release Tablets

40 mg Pantoprazole (as pantoprazole sodium sesquihydrate)

Read this carefully before you start taking RIVA-PANTOPRAZOLE and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about RIVA- PANTOPRAZOLE.

#### **What is RIVA-PANTOPRAZOLE used for?**

RIVA-PANTOPRAZOLE is used to treat stomach acid related problems. This includes:

- **Stomach ulcer.**  
A stomach ulcer is a sore on the lining of the stomach. This is also known as a gastric ulcer.
- **Duodenal ulcer.**  
A sore on the lining of the duodenum. The duodenum is the first part of the small intestine.
- **Reflux esophagitis.**  
This is a severe form of heartburn.
- **Symptoms of gastro-esophageal reflux disease (GERD).**  
The symptoms include heartburn and acid regurgitation. GERD is a condition in which stomach acid backs up into your esophagus.
- **When taking Non-steroidal anti-inflammatory drugs (NSAIDs).**  
Stops stomach and duodenal ulcers from forming.

#### **How does RIVA-PANTOPRAZOLE work?**

RIVA-PANTOPRAZOLE is a proton pump inhibitor. It reduces the amount of acid your stomach makes.

#### **What are the ingredients in RIVA-PANTOPRAZOLE?**

Medicinal ingredients: pantoprazole sodium sesquihydrate

Non-medicinal ingredients: Calcium stearate, cellulose microcrystalline, crospovidone, ferric oxide black, ferric oxide red, ferric oxide yellow, hydroxypropylcellulose, hypromellose, macrogol, methacrylic acid – ethyl acrylate copolymer, polysorbate 80, ponceau 4R aluminium lake, povidone, quinoline yellow aluminium lake, shellac, silica-colloidal anhydrous, sodium carbonate anhydrous, sodium laurilsulfate, titanium dioxide, triethyl citrate.

#### **RIVA-PANTOPRAZOLE comes in the following dosage forms:**

Delayed-Release tablets 40 mg pantoprazole (as pantoprazole sodium sesquihydrate).

**Do not use RIVA-PANTOPRAZOLE if:**

- You are allergic to any of its ingredients. (See What are the ingredients in RIVA-PANTOPRAZOLE?)
- You are taking rilpivirine.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take RIVA-PANTOPRAZOLE. Talk about any health conditions or problems you may have, including if you:**

- are taking other medications (see The following may interact with RIVA-PANTOPRAZOLE).
- are pregnant or plan to become pregnant.
- are breastfeeding or plan to breast feed. Pantoprazole has been found in human breast milk. Talk with your doctor.
- suffer these effects:
  - unexplained weight loss.
  - severe or persistent diarrhea.
  - repeated vomiting.
  - vomiting blood.
  - dark stools.
  - tiredness (anemia).
  - difficulty in swallowing.
  - Have a history of liver problems.
- have low magnesium in the body, which may cause symptoms such as:
  - rapid heartbeat.
  - dizziness, seizures.
  - muscle cramping, twitches or spasms.
- are due to have a specific blood test (Chromogranin A).

**Other warnings you should know about:**

You should take RIVA-PANTOPRAZOLE exactly as prescribed. You will use the lowest dose and shortest time suitable for your condition. Talk to your doctor if you have any concerns about your treatment.

Depending on your condition, your doctor may tell you to use this type of medicine (proton pump inhibitors) for a longer period.

Using proton pump inhibitors for a long time (every day for a year or longer) may increase risks of broken bones of the hip, wrist or spine. Talk to your doctor about this risk.

Long term use of proton pump inhibitors may interfere with the absorption of Vitamin B<sub>12</sub> from the diet. This may cause a shortage of Vitamin B<sub>12</sub> in your body. Talk to your doctor.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with RIVA-PANTOPRAZOLE:**

Warfarin, atazanavir, nelfinavir, saquinavir/ritonavir, methotrexate.

**How to take RIVA-PANTOPRAZOLE:**

- Take RIVA-PANTOPRAZOLE in the morning.
  - with or without food
- Swallow the tablet(s) whole with water.
- Do not crush or chew the tablet(s).

**Usual adult dose:**

Your doctor will have told you what dose to take for your condition. Follow your doctor's directions carefully as they may be different from the information provided in this leaflet.

If you think you have taken too much RIVA-PANTOPRAZOLE, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

**Missed dose:**

If you miss a dose, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose. Take the next dose at your regular time. Do not double doses.

**What are possible side effects from using RIVA-PANTOPRAZOLE?**

Like all medicines, RIVA-PANTOPRAZOLE may cause side effects. Side effects have generally been mild and did not last a long time. These are not all the possible side effects you may feel when taking RIVA-PANTOPRAZOLE.

The most common side effects are:

- headache.
- diarrhea.
- nausea.

Your symptoms may get worse after stopping your medication. This may occur as your stomach may increase the production of acid.

SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>RARE</b>			
Disturbances in vision. Most cases reported are not serious.			✓
<b>ISOLATED CASES</b>			
Liver damage. Symptoms include yellow tinge to the skin and eyes.			✓

Serious skin reactions. Symptoms include widespread rash, itching, or hives. Peeling of the skin, blisters on the skin, mouth, nose, eyes and genitals are other symptoms.			✓
Muscle wasting			✓
<i>Clostridium difficile</i> colitis (bowel inflammation). Symptoms include severe (watery or bloody) diarrhea, fever, and abdominal pain or tenderness.			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### Storage:

Store in a dry place at room temperature (between 15°C and 30 °C). Keep out of reach and sight of children.

### If you want more information about RIVA-PANTOPRAZOLE:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website(<http://hc-sc.gc.ca/index-eng.php>); the manufacturer's website [www.labriva.com](http://www.labriva.com) or by calling 1-800-3637988.

This leaflet was prepared by Laboratoire Riva Inc.

Last revised: July 03, 2018